{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:59:56Z","timestamp":1790283596378,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03466-8","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:15:13Z","timestamp":1783628113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Contract Manufacturing in Antibody\u2013Drug Conjugate (ADC) Drug Substance Development \u2013 Strategies for Successful Engagement"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1400-6767","authenticated-orcid":false,"given":"Conor S.","family":"Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"6","key":"3466_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"3466_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00064-w","author":"P Flynn","year":"2024","unstructured":"Flynn P, Suryaprakash S, Grossman D, Panier V, Wu J. The antibody\u2013drug conjugate landscape. Nat Rev Drug Discov. 2024. https:\/\/doi.org\/10.1038\/d41573-024-00064-w.","journal-title":"Nat Rev Drug Discov"},{"key":"3466_CR3","unstructured":"Beacon ADC Database, Hanson Wade; https:\/\/beacon-intelligence.com\/solutions\/adc-database\/"},{"issue":"16","key":"3466_CR4","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody\u2013drug conjugates. Chem Soc Rev. 2019;48(16):4361\u201374. https:\/\/doi.org\/10.1039\/c8cs00676h.","journal-title":"Chem Soc Rev"},{"key":"3466_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ejmech.2019.06.044","volume":"179","author":"SJ Gregson","year":"2019","unstructured":"Gregson SJ, Barrett AM, Patel NV, Kang GD, Schiavone D, Sult E, et al. Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual \u03b2-glucuronide and dipeptide triggers. Eur J Med Chem. 2019;179:591\u2013607.","journal-title":"Eur J Med Chem"},{"key":"3466_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody\u2013drug conjugates. J Hematol Oncol. 2023;16:3. https:\/\/doi.org\/10.1186\/s13045-022-01397-y.","journal-title":"J Hematol Oncol"},{"key":"3466_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-024-01507-y","author":"T Journeaux","year":"2024","unstructured":"Journeaux T, Bernardes GJL. Homogeneous multi-payload antibody\u2013drug conjugates. Nat Chem. 2024. https:\/\/doi.org\/10.1038\/s41557-024-01507-y.","journal-title":"Nat Chem"},{"issue":"12","key":"3466_CR8","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1016\/j.xphs.2023.09.007","volume":"112","author":"K Bechtold-Peters","year":"2023","unstructured":"Bechtold-Peters K, Ruggiero A, Vriezen N, Ihle N, Klein A, Morgan C, et al. CMC regulatory considerations for antibody-drug conjugates. J Pharm Sci. 2023;112(12):2965\u201380. https:\/\/doi.org\/10.1016\/j.xphs.2023.09.007.","journal-title":"J Pharm Sci"},{"key":"3466_CR9","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Development and manufacture of drug substances Q11. 2012. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q11_Guideline.pdf. Accessed 01\/03\/2026."},{"key":"3466_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-020-00457-5","volume":"22","author":"MM Papathanasiou","year":"2020","unstructured":"Papathanasiou MM, Kenyon A. Chemistry, manufacturing, and control considerations for antibody\u2013drug conjugates. AAPS J. 2020;22:1\u201315. https:\/\/doi.org\/10.1208\/s12248-020-00457-5.","journal-title":"AAPS J"},{"issue":"2","key":"3466_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","volume":"8","author":"Q Fan","year":"2025","unstructured":"Fan Q, Chen H, Wei G, Wei D, Wang Z, Zhang L, et al. A review of conjugation technologies for antibody drug conjugates. Antibody Ther. 2025;8(2):157\u201370. https:\/\/doi.org\/10.1093\/abt\/tbaf010.","journal-title":"Antibody Ther"},{"key":"3466_CR12","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Pharmaceutical development Q8(R2). 2009. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf. Accessed 01\/03\/2026."},{"key":"3466_CR13","volume-title":"EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Annex 1: Manufacture of sterile medicinal products","author":"European Commission","year":"2022","unstructured":"European Commission. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Annex 1: Manufacture of sterile medicinal products. Brussels: European Commission; 2022."},{"key":"3466_CR14","volume-title":"Baseline\u00ae guide volume 7: Risk-based manufacture of pharmaceutical products (Risk-MaPP)","author":"International Society for Pharmaceutical Engineering (ISPE)","year":"2017","unstructured":"International Society for Pharmaceutical Engineering (ISPE). Baseline\u00ae guide volume 7: Risk-based manufacture of pharmaceutical products (Risk-MaPP). 2nd ed. North Bethesda, MD: ISPE; 2017.","edition":"2"},{"key":"3466_CR15","unstructured":"European Medicines Agency. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities; EMA\/CHMP\/CVMP\/SWP\/169430\/2012"},{"issue":"11","key":"3466_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17111397","volume":"17","author":"S Luo","year":"2025","unstructured":"Luo S, Bulos J, Uroza R, Zhao Y, Pan X, Su Y, et al. Insights into photo degradation and stabilization strategies of antibody\u2013drug conjugates with Camptothecin payloads. Pharmaceutics. 2025;17(11):1397.","journal-title":"Pharmaceutics"},{"key":"3466_CR17","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Stability testing: photostability testing of new drug substances and products Q1B. 1996. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q1B_Guideline.pdf. Accessed 01\/03\/2026."},{"key":"3466_CR18","volume-title":"Technology Transfer Good Practice Guide","author":"International Society for Pharmaceutical Engineering (ISPE)","year":"2010","unstructured":"International Society for Pharmaceutical Engineering (ISPE). Technology Transfer Good Practice Guide. Tampa, FL: ISPE; 2010."},{"key":"3466_CR19","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Pharmaceutical quality system Q10. 2008. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q10_Guideline.pdf. Accessed 01\/03\/2026."},{"key":"3466_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"JW Buecheler","year":"2020","unstructured":"Buecheler JW, Winzer M, Tonillo J, Weber C, Gieseler H. Payload selection for antibody\u2013drug conjugates. Nat Rev Drug Discov. 2020;19:529\u201346. https:\/\/doi.org\/10.1038\/s41573-020-0076-6.","journal-title":"Nat Rev Drug Discov"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03466-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:03:05Z","timestamp":1790280185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03466-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3466"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03466-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CSB is an employee of Piramal Pharma Solutions, a company which provides bioconjugate CDMO services.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI assisted copy-editing was used to check for grammar, formatting and repetition in the final text.","order":2,"name":"Ethics","label":"A.I. Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"255"}}